SCHEMBL6173530

SCHEMBL6173530

c1c[nH]c(C2CCCCN2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 3/20 0.45
CHRNA4 P43681 3/20 0.45
MEN1 O00255 2/20 0.45
CYP2D6 P10635 2/20 0.45
CYP2C19 P33261 2/20 0.45
KMT2A Q03164 2/20 0.45
CHRNA7 P36544 2/20 0.45
POLB P06746 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2A6 P11509 1/20 0.45
CYP2C9 P11712 1/20 0.45
ADRA1A P35348 6/20 0.40
ADRA1D P25100 3/20 0.40
ADRA1B P35368 2/20 0.40
ADRA2A P08913 1/20 0.40
PARP1 P09874 3/20 0.36
AURKA O14965 1/20 0.36
SCN10A Q9Y5Y9 1/20 0.35
NISCH Q9Y2I1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7666599 0.94 CHRNB2 (0.43) CHRNB2CHRNA4MEN1CYP2D6CYP2C19
SCHEMBL16405081 0.94 CHRNB2 (0.43) CHRNB2CHRNA4MEN1CYP2D6CYP2C19
SCHEMBL634724 0.94 CHRNB2 (0.43) CHRNB2CHRNA4MEN1CYP2D6CYP2C19
Hydrochloric Acid SCHEMBL28603590 0.93 CHRNB2 (0.42) CHRNB2CHRNA4MEN1CYP2D6CYP2C19
Hydrochloric Acid SCHEMBL15169508 0.93 CHRNB2 (0.42) CHRNB2CHRNA4MEN1CYP2D6CYP2C19
Hydrochloric Acid SCHEMBL27828833 0.93 CHRNB2 (0.42) CHRNB2CHRNA4MEN1CYP2D6CYP2C19
Naphthalene SCHEMBL27966102 0.85 ADRA1A (0.45) CHRNB2CHRNA4MEN1CYP2D6CYP2C19
Acetic Acid SCHEMBL27758904 0.84 CREBBP (0.38) CHRNB2CHRNA4CHRNA7ADRA1AADRA1D
SCHEMBL27651097 0.74 ADRA1A (0.40) SMN1; SMN2ADRA1AADRA1DADRA1BADRA2A
SCHEMBL184451 0.74 ADRA1A (0.55) SMN1; SMN2ADRA1AADRA1DADRA1BADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5071855-A Antihistamines, antiallergens DOMPE FARMACEUTICI SPA (IT) 1991-12-10 US claimed
EP-0397614-A2 Pharmacologically active piperdinylimidazopyridines DOMPE' FARMACEUTICI S.p.A. (IT) 1990-11-14 EP claimed
CN-109851610-B Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists 赫普泰雅治疗有限公司 2021-09-21 CN disclosed
EP-1349850-B1 SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES SOD CONSEILS RECH APPLIC (FR) 2005-09-07 EP disclosed
EP-1349850-B1 SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES SOD CONSEILS RECH APPLIC (FR) 2005-09-07 EP disclosed
CN-1214025-C Sodium channel modulators derived from 2-piperidylimidazoles SOD CONSEILS RECH APPLIC (FR) 2005-08-10 CN disclosed
CN-1214025-C Sodium channel modulators derived from 2-piperidylimidazoles SOD CONSEILS RECH APPLIC (FR) 2005-08-10 CN disclosed
CN-1214025-C Sodium channel modulators derived from 2-piperidylimidazoles SOD CONSEILS RECH APPLIC (FR) 2005-08-10 CN disclosed
US-20040077640-A1 Sodium channel modulators derived from 2-piperidylimidazoles SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-04-22 US disclosed
US-20040077640-A1 Sodium channel modulators derived from 2-piperidylimidazoles SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-04-22 US disclosed
US-20040077640-A1 Sodium channel modulators derived from 2-piperidylimidazoles SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-04-22 US disclosed
CN-1483029-A Sodium channel modulators derived from 2-piperidylimidazoles ��ѧ�о���Ӧ����ѯ��˾ 2004-03-17 CN disclosed
CN-1483029-A Sodium channel modulators derived from 2-piperidylimidazoles ��ѧ�о���Ӧ����ѯ��˾ 2004-03-17 CN disclosed
CN-1483029-A Sodium channel modulators derived from 2-piperidylimidazoles ��ѧ�о���Ӧ����ѯ��˾ 2004-03-17 CN disclosed
EP-1349850-A1 SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) 2003-10-08 EP disclosed
EP-1349850-A1 SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) 2003-10-08 EP disclosed
WO-2002053559-A1 SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2002-07-11 WO disclosed
WO-2002053559-A1 SODIUM CHANNEL MODULATORS DERIVED FROM 2-PIPERIDYLIMIDAZOLES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2002-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077640-A1 Sodium channel modulators derived from 2-piperidylimidazoles KCNH1, HCN4, KCNH2 CHRNB2 342/4885CHRNA4 125/4885MEN1 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.